Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
Public ClinicalTrials.gov record NCT04904276. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy (FORTE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP in adult patients who have an insufficient response to prior therapy (steroids ± immunoglobulins).
Study identification
- NCT ID
- NCT04904276
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 18, 2021 (Actual)
- Primary completion
- Nov 17, 2022 (Actual)
- Completion
- Nov 17, 2022 (Actual)
- Last update posted
- Mar 15, 2024
2021 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Advanced Research | Tamarac | Florida | 33321 | — |
| Simmons Cancer Institute at Southern Illinois University | Springfield | Illinois | 62702 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| Saint Agnes Hospital | Baltimore | Maryland | 21229 | — |
| The Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Maryland Oncology Hematology, P.A | Clinton | Maryland | 20735 | — |
| Maryland Oncology Hematology, P.A | Columbia | Maryland | 21044 | — |
| Maryland Oncology Hematology, P.A | Rockville | Maryland | 20850 | — |
| Maryland Oncology Hematology, P.A | Silver Spring | Maryland | 20904 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Washington University | St Louis | Missouri | 63130 | — |
| Regional Cancer Care Associates, LLC | Little Silver | New Jersey | 07739 | — |
| New York Medical College Westchester Medical Center | Valhalla | New York | 10532 | — |
| New York Medical College | Valhalla | New York | 10595 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04904276, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2024 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04904276 live on ClinicalTrials.gov.